Axsome Therapeutics Stock News

Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time

Vertex Pharmaceuticals is awaiting a regulatory decision on what may become its next blockbuster. Axsome Therapeutics aims to launch several products over the next few years.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Axsome Therapeutics has two approved products and a promising pipeline. Beam Therapeutics' base-editing technology could be a huge moneymaker over time.

Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.

Axsome Therapeutics (AXSM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.06 per share a year ago.

Axsome Therapeutics' novel treatments for central nervous system disorders gain traction, with promising revenues from drugs Auvelity and Sunosi. Despite the current lack of profitability, Axsome show

The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand that one o

Axsome Therapeutics' current drugs and pipeline programs look especially promising. Brookfield Renewable could double in six years if it hits the low end of its projected growth range.

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.

MercadoLibre and Axsome Therapeutics are two exciting growth stocks that are worth a look. NextEra Energy and Starbucks can afford to continue raising their dividends year after year.

Axsome Therapeutics (NASDAQ: AXSM ) stock is heading lower on Wednesday as investors react to the company pricing a public share offering. Axsome Therapeutics is selling 3 million shares of AXSM stock

Axsome Therapeutics' exciting pipeline promises a bright future for the company. CRISPR Therapeutics is on the verge of what could be the first of many approvals.

Axsome Therapeutics' pipeline features multiple potentially big winners. CRISPR Therapeutics could be at the beginning of a long-term success story.

With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy.